Phase III trials in NMOSD
Cladribine and time to SPMS
Hypogammaglobulinemia
Cannabis and cognition
Concussion and MS
Clinical Tip of the day Read More
Latest News
ECTRIMS Poster Picks – Thursday, September 12
September 12, 2019Thursday, September 12, 2019 – Today’s poster session runs from 5:15-7:15 pm
Here are Steven’s Top poster topics at ECTRIMS for Thursday, September 12. Read More
ECTRIMS Poster Picks – Wednesday, September 11
September 11, 2019Wednesday, September 11, 2019 – Today’s poster session runs from 5:15-7:15 pm
Here are Steven’s Top poster topics at ECTRIMS for Wednesday, September 11, 2019. Read More
Progressive MS trials – design and interpretation
September 4, 2019Part 2
Part 1 of this article examined how the definitions of secondary-progressive and primary-progressive MS (SPMS, PPMS) have evolved and the contentious role that focal inflammatory activity has played (See Secondary-progressive MS: conceptual and practical challenges, NeuroSens, April 17, 2019). One shift has been to view the phenotypes of SPMS and PPMS as virtually indistinguishable with respect to their pathophysiology and clinical course, so both SPMS and PPMS trials will be considered here. Read More